Collectionner le produit
Détails du produit
Synonyms
CD39, ENTPD1, NTPDase 1, Entpd1, Ecto-ATPDase 1, Ecto-ATPase 1
Source
Human CD39, Mouse IgG2a Fc Tag (CD9-H5253) is expressed from human 293 cells (HEK293). It contains AA Thr 38 - Val 478 (Accession # P49961-1).
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 77.3 kDa. The protein migrates as 95-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 20 mM Tris, 500 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human CD39, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Human CD39, Mouse IgG2a Fc Tag (Cat. No. CD9-H5253) at 1 μg/mL (100 μL/well) can bind Anti-CD39 Antibody, Human IgG1 with a linear range of 0.078-2.5 ng/mL (QC tested).
Protocol
Bioactivity
Measured by its ability to hydrolyze the 5’-phosphate group from the substrate adenosine-5’-triphosphate (ATP). The specific activity is > 800 pmol/min/μg (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Ectonucleoside triphosphate diphosphohydrolase 1
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
11 Détails
- Étape de développement la plus élevée：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
